



Centre for
Heart Lung Innovation
UBC and St. Paul's Hospital

Centre for Heart Lung Innovation Research in Progress (R.I.P.)



Development of Oncolytic Coxsackievirus B3 for Breast Cancer Therapy

Amirhossein Bahreyni
Phd Candidate
Dr. Honglin Luo

Monday, Oct 24th, 2022
9:00 – 10:00 a.m.

Gourlay Conference RM 103
Zoom Video Conference
(Meeting ID: 693 1997 7044; Passcode: 030679)

"Breast cancer is the leading cause of cancer mortality in women worldwide. Massive side effects observed in current treatments like chemotherapy and lack of appropriate treatment options for patients with chemotherapy-resistant or recurrent cancers, forcing the field toward the rapid development of novel therapies. Oncolytic viruses have emerged as effective procedures for treatment of various malignancies. Our previous research has revealed that miRNA-modified Coxsackievirus B3 (CVB3) exhibits an excellent anti-tumor efficacy against KRASmut lung adenocarcinoma and TP53mut/RB1mut small cell lung cancer with minimal toxicity. In the current study, I extend our research to breast cancer to evaluate the potency and safety of genetically engineered CVB3 to be applied as a novel treatment against breast tumor, particularly triple-negative breast cancer."

This event is a Self-Approved Group Learning Activity as defined by the Maintenance Certification Program of the Royal College of Physicians and Surgeons of Canada



a place of mind



THE LUNG ASSOCIATION™
British Columbia



HEART &
STROKE
FOUNDATION
OF BC & YUKON

Finding answers. For life.